ClearPoint Neuro, Inc.
NASDAQ•CLPT
CEO: Mr. Joseph Michael Burnett
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Contact Information
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
Market Cap
$275.17M
P/E (TTM)
-11.4
30
Dividend Yield
--
52W High
$30.10
52W Low
$8.63
52W Range
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$8.86M+9.10%
4-Quarter Trend
EPS
-$0.21+16.67%
4-Quarter Trend
FCF
-$3.32M+174.15%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Total Revenue Increased 9% Q3 2025 total revenue reached $8.9M, a 9% increase; 9M revenue grew 12% to $26.6M.
Gross Margin Expansion Noted Q3 Gross Margin improved to 63% compared to 60% last year, driven by favorable revenue mix.
Secured Major Debt Financing Secured $28.7M net proceeds from 2025 NPA issuance, supplementing $3.3M from 2025 SPA offering.
Service Revenue Strong Growth Q3 Service revenue surged 32% to $3.5M, offsetting slight product revenue decline for the quarter.
Risk Factors
Net Loss Widened Significantly Q3 Net Loss increased 18% to $(5.9M); 9M Net Loss widened 31% to $(17.8M).
Operating Expenses Increased Nine months G&A expenses rose 27% to $11.1M, driven by higher personnel and professional fees.
Debt Covenants Exposure Obligations under 2025 NPA include covenants; failure to comply risks acceleration of outstanding debt principal.
Biologics Regulatory Uncertainty Growth in biologics business depends on timely FDA approval and evolving regulatory criteria for CGTs.
Outlook
IRRAS Acquisition Expected Closing Merger Agreement signed November 6, 2025, with expected closing in the fourth quarter of 2025.
Additional Funding Contingent Agreement secured to access $20.0M additional funding contingent upon successful closing of IRRAS transaction.
Liquidity Position Adequate Management believes current cash balances of $38.2M are sufficient for operations over next twelve months.
Biologics Partner Base Expanding Partner relationships for biologics/drug delivery grew to over 60 as of September 30, 2025.
Peer Comparison
Revenue (TTM)
$912.10M
$854.40M
$824.50M
Gross Margin (Latest Quarter)
83.5%
79.0%
78.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| TYRA | $1.84B | -17.2 | -41.2% | 2.1% |
| OLMA | $1.77B | -12.9 | -41.5% | 1.3% |
| AXGN | $1.51B | -87.1 | -13.4% | 8.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.5%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:Mar 11, 2026
EPS:-$0.22
|Revenue:$10.05M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data